1. Comparison of programmed death-ligand 1 expression in adenocarcinoma and squamous cell carcinoma of the cervix in paraffin blocks of patients with cervical cancer.
- Author
-
Hosseini MS, Shafizadeh F, Bahremani MH, Farzaneh F, Ashrafganjoei T, Arab M, Talayeh M, Jafari F, and Abdshah A
- Subjects
- Humans, Female, Cross-Sectional Studies, Middle Aged, Adult, Paraffin Embedding, Biomarkers, Tumor metabolism, Biomarkers, Tumor analysis, Iran, Aged, Immunohistochemistry, Uterine Cervical Neoplasms pathology, Uterine Cervical Neoplasms metabolism, Uterine Cervical Neoplasms therapy, B7-H1 Antigen metabolism, B7-H1 Antigen analysis, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell metabolism, Carcinoma, Squamous Cell therapy, Adenocarcinoma pathology, Adenocarcinoma metabolism
- Abstract
Aims: Cervical cancer (CC) is a common malignancy in women, predominantly caused by human papillomavirus. The most subtypes are adenocarcinomas (AC) and squamous cell carcinomas (SCC), which show various features and treatment responses. Programmed death-ligand 1 (PD-L1) and programmed cell death protein 1 (PD-1) as Immune checkpoint molecules, play a role in immune evasion. We investigated PD-L1 expression in AC and SCC of the cervix and explored its link to clinical characteristics., Methods and Results: The present cross-sectional research was done between 2016 and 2022 on samples in Shahid Beheshti University of Medical Sciences-affiliated hospitals in Iran. Histological tissue samples of CCs (16 AC and 48 SCC) were assessed, and clinical information was obtained by reviewing their medical documents. PD-L1 expression was evaluated by immunohistochemistry and we used the combined positive score. SCC cases showed a higher (not significant) PD-L1 expression. The PD-L1 expression and clinical characteristics were not significantly correlated in both subgroups., Conclusion: Although SCC cases exhibited higher PD-L1 expression, this difference was non-significant. More investigations should highlight the role of PD-L1 in CC and the potential benefits of immunotherapy., (© 2024 The Authors. Cancer Reports published by Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF